Durvalumab: Phase I started

The Heptares Therapeutics Ltd. subsidiary of Sosei Group Corp. (Tokyo:4565, Tokyo, Japan) said AstraZeneca began an

Read the full 163 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE